Intuitive Surgical’s Market Leadership Bolstered by dV5 System Advancements: A Strong Buy Recommendation

Analyst David Rescott from Robert W. Baird maintained a Buy rating on Intuitive Surgical (ISRG – Research Report) and keeping the price target at $436.00.

David Rescott has given his Buy rating due to a combination of factors surrounding Intuitive Surgical’s market leadership and advancements in its technology. Intuitive Surgical, recognized for spearheading the robotic-assisted surgery (RAS) space, has made significant strides with its next-generation dV5 system. The recent SAGES Conference provided Rescott with insights into the actual applications and enhancements of the dV5 system, which is set to expand the company’s reach in soft tissue surgical robotics. The system’s potential to increase RAS penetration through a growing installed base and higher utilization of existing systems underscores its market potential. Key barriers to broader RAS adoption such as costs, capacity, and surgeon hesitancy are believed to be mitigated by the dV5’s features, which in turn should boost Intuitive Surgical’s installed base growth and procedure growth globally.

Notably, haptic feedback technology in the dV5 is expected to be a major catalyst for adoption, especially among new users. While seasoned surgeons who are loyal to traditional laparoscopic methods might not be swayed, the new technology is likely to attract top talent and support the training of new surgeons, potentially enhancing safety and outcomes. Improvements in operating room (OR) efficiency through features like tower integration are also anticipated to facilitate capacity expansion, further driving adoption. Feedback from physicians already using the dV5 system indicates real-world benefits such as reduced OR time and increased throughput. These benefits, along with the system’s potential for cost savings and enhanced data tracking, provide tangible value to hospital administrators, affirming Rescott’s positive outlook on Intuitive Surgical’s stock.

In another report released yesterday, Leerink Partners also maintained a Buy rating on the stock with a $449.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Intuitive Surgical (ISRG) Company Description:

Intuitive Surgical, Inc. manufactures and develops robotic-assisted products, most notably with the da Vinci surgical system and related instruments and accessories, to improve clinical outcomes of patients through minimally invasive surgery. Its products include Da Vinci and Ion. The company was founded in 1995 and is headquartered in Sunnyvale, California.